Plasmapheresis in TTP Mimics: When Are We Getting It Wrong?

Plasmapheresis in TTP Mimics: When Are We Getting It Wrong?

---

---

 

---

Introduction

Plasmapheresis has revolutionized the treatment of thrombotic thrombocytopenic purpura (TTP), reducing mortality rates from nearly 100% to less than 10–20%. Despite this progress, diagnostic uncertainty remains a key clinical challenge. Data from the Oklahoma TTP-HUS Registry revealed that 7% of 415 patients initially diagnosed with TTP were ultimately found to have systemic infections that mimicked the condition.

These mimics are particularly problematic because they often present with clinical features indistinguishable from true TTP. Notably, over half (52%) of patients with systemic infections exhibited the full clinical “pentad” traditionally associated with TTP. As a result, differentiating TTP from its mimics at presentation is often difficult, leading to potential misdiagnosis and inappropriate treatment.

Given the high early mortality associated with untreated TTP, the American Society for Apheresis recommends initiating therapeutic plasma exchange (TPE) within 4–8 hours of diagnosis. However, this urgency must be weighed against the risks of unnecessary intervention, especially in cases where the diagnosis is uncertain.

Treatment duration with TPE varies widely among patients with TTP, ranging from 4 to 21 sessions, with an average of 13. This variability underscores the need for an individualized approach to determining when to discontinue plasmapheresis, guided by clinical response and laboratory markers.

While the introduction of caplacizumab has improved outcomes and reduced the duration of TPE in some patients, plasmapheresis remains the cornerstone of initial TTP management, particularly when diagnostic clarity is lacking. A careful, evidence-based approach is essential to balance timely intervention with the avoidance of overtreatment in mimicking conditions.

 

Common Clinical Presentations That Mimic TTP

The accurate diagnosis of thrombotic thrombocytopenic purpura (TTP) presents substantial challenges due to several conditions that share clinical and laboratory features with this rare disorder. Recognizing these mimics is essential for appropriate therapeutic decision-making regarding plasmapheresis initiation.

Systemic infections with overlapping features

Systemic infections frequently masquerade as TTP, creating diagnostic dilemmas. In the Oklahoma TTP-HUS Registry, 7% of 415 patients initially diagnosed with TTP ultimately had their presenting features attributed to various systemic infections. Notably, all these patients demonstrated microangiopathic hemolytic anemia and thrombocytopenia, while 87% exhibited neurologic abnormalities. Moreover, over half (52%) presented with the complete “pentad” of clinical features traditionally associated with TTP.

The diagnostic challenge intensifies when considering that 16% of patients with infection-related TMA had ADAMTS13 activity below 10%, mimicking the characteristic finding of true TTP. Seventeen different infectious etiologies were documented in the Oklahoma Registry, with a literature review identifying infections with 41 different bacteria, viruses, and fungi capable of mimicking TTP. Importantly, patients with systemic infections, compared to those with severe ADAMTS13 deficiency, displayed more frequent fever, coma, renal failure, and the complete clinical pentad.

Malignancy-associated microangiopathy

Cancer-associated thrombotic microangiopathy primarily affects patients with mucin-producing adenocarcinomas and disseminated malignancies. Among cancer-associated TMAs, gastric carcinoma represents the most common type (26.2%), followed by breast (21.4%), prostate (13.7%), and lung cancer (9.5%). The incidence ranges from 0.25 to 0.45 persons per million, with approximately 5.7% of patients with metastatic carcinoma developing MAHA.

Several features help distinguish cancer-associated TMA from TTP. These include older age at presentation (mid-50s versus early-40s with TTP), ADAMTS13 activity closer to 50% rather than below 10%, prominent respiratory symptoms in over 70% of cases, and bone pain. Additionally, these patients typically fail to respond to plasma exchange. The pathophysiology involves bone marrow infiltration by tumor cells causing endothelial cell injury and release of ultra-large VWF multimers.

HELLP syndrome and preeclampsia

HELLP syndrome (Hemolysis, Elevated Liver enzymes, Low Platelets) and preeclampsia create particular diagnostic challenges during pregnancy. While both conditions share backgrounds of endothelial injury and microvascular thrombi with TTP, they have different etiologies and management approaches.

The differential diagnosis becomes particularly complex in late pregnancy due to significant overlap in clinical presentations. Although HELLP syndrome occurs in approximately 1% of pregnancies compared to TTP’s incidence of 1/100,000 pregnancies, distinguishing between them remains critical. Patients with preeclampsia or eclampsia may exhibit microangiopathic hemolytic anemia, seizures, and thrombocytopenia, though hematologic manifestations generally appear milder than in TTP. A platelet count below 20 × 10^9/L in the absence of DIC typically favors TTP diagnosis.

Vitamin B12 deficiency and pseudo-TMA

Pseudo-thrombotic microangiopathy (pseudo-TMA) represents a rare manifestation of vitamin B12 deficiency, occurring in only 2.5% of deficiency cases. This condition presents with hemolytic anemia, thrombocytopenia, and schistocytosis, closely mimicking TTP. Due to its rarity, approximately 38.8% of pseudo-TMA cases are misdiagnosed as TTP, resulting in unnecessary plasmapheresis instead of appropriate B12 supplementation.

In contrast to true TTP, vitamin B12 deficiency-associated pseudo-TMA typically features more severe anemia, higher mean corpuscular volume, higher LDH levels (often >3000 U/L), lower reticulocyte count, and lower neutrophil count. Furthermore, the hemolysis in cobalamin deficiency occurs without intravascular platelet aggregates or microthrombi, which represent defining hallmarks of thrombotic microangiopathies. Accurate diagnosis prevents unnecessary plasma exchange therapy and ensures prompt initiation of vitamin B12 supplementation, with most patients responding well to this targeted intervention.

 

 

ADAMTS13 Activity and Its Diagnostic Role

The measurement of ADAMTS13 activity serves as a cornerstone in differentiating thrombotic thrombocytopenic purpura from other thrombotic microangiopathies, subsequently guiding appropriate therapeutic interventions. ADAMTS13, a disintegrin and metalloproteinase with thrombospondin type 1 motif member 13, functions as the von Willebrand factor cleaving protease in plasma, playing a vital role in preventing microvascular thrombosis.

Severe deficiency (<10%) as a diagnostic anchor

ADAMTS13 activity below 10% stands as the defining laboratory characteristic of TTP. This threshold demonstrates remarkable diagnostic accuracy with sensitivity ranging from 89% to 100% and specificity from 94.6% to 100% in distinguishing TTP from other thrombotic microangiopathies. Nevertheless, the interpretation of ADAMTS13 activity must always occur within the appropriate clinical context.

Approximately two-thirds of patients with a clinical diagnosis of idiopathic TTP exhibit ADAMTS13 activity levels below 10%. This severe deficiency results primarily from autoantibodies that inhibit ADAMTS13 in acquired TTP, whereas mutations in the ADAMTS13 gene cause hereditary TTP (Upshaw-Schulman syndrome). The presence of inhibitory antibodies can be detected through mixing studies, wherein patient plasma mixed with normal plasma shows persistent inhibition of ADAMTS13 activity.

Certain preanalytical factors can affect ADAMTS13 activity measurement. Free hemoglobin (>2 g/dL) and hyperbilirubinemia (>15 mg/dL) may reduce measured ADAMTS13 activity. Likewise, prior plasma exchange or transfusion can artificially normalize ADAMTS13 levels, potentially masking the diagnosis. Thus, blood samples for ADAMTS13 testing should ideally be collected before initiating plasma therapy.

False positives in infection-related TMAs

Despite its high specificity, severely reduced ADAMTS13 activity (<10%) occasionally occurs in conditions other than TTP. Various studies have documented severe ADAMTS13 deficiency in certain patients with sepsis-induced disseminated intravascular coagulation. Among patients with infection-related thrombotic microangiopathy, approximately 16% demonstrated ADAMTS13 activity below 10%, creating a diagnostic challenge.

Some researchers have proposed using a slightly higher threshold of <20% for ADAMTS13 activity to improve diagnostic sensitivity. One retrospective study indicated that this modified cutoff achieved 100% sensitivity and 99% specificity, with a positive predictive value of 91% and a negative predictive value of 100%. Nonetheless, most institutions continue to use the traditional <10% threshold as the primary diagnostic criterion.

The Oklahoma TTP-HUS Registry identified multiple cases where severe ADAMTS13 deficiency occurred in patients with documented systemic infections rather than true TTP. This overlap highlights the complexity of differentiating TTP from infection-related TMAs based solely on ADAMTS13 activity. In these situations, careful clinical assessment and monitoring of treatment response become essential.

Limitations of ADAMTS13 testing turnaround time

A major challenge in utilizing ADAMTS13 activity for acute management decisions involves the lengthy turnaround time for test results. Standard ADAMTS13 assays typically require processing in specialized reference laboratories, often resulting in delays of several days. The standard testing process may take 1-3 days for activity measurement, 2-4 days for inhibitor testing, and up to 7 days for antibody assays.

Because of these delays, therapeutic plasma exchange (TPE) must frequently be initiated empirically while ADAMTS13 results remain pending. This approach aligns with guidelines recommending prompt TPE initiation in suspected TTP cases but may lead to unnecessary treatment in patients ultimately diagnosed with TTP mimics.

Newer ADAMTS13 assays utilizing fluorescence resonance energy transfer (FRET) technology offer faster results, potentially within 2 hours compared to 2-3 days for traditional methods. These rapid assays could substantially reduce unnecessary TPE use, decrease the need for transferring patients to specialized centers, and minimize risks associated with inappropriate TPE. Furthermore, early exclusion of TTP through rapid testing allows faster initiation of appropriate therapies for alternative diagnoses, potentially improving outcomes across the spectrum of thrombotic microangiopathies.

 

When Plasmapheresis Is Misapplied in TTP Mimics

Therapeutic plasma exchange (TPE) remains essential for treating true thrombotic thrombocytopenic purpura, yet its application in TTP mimics often leads to unnecessary procedures and potential complications. Identifying situations where plasmapheresis is misapplied helps clinicians avoid inappropriate interventions while ensuring timely treatment for genuine cases.

Plasmapheresis in sepsis-induced TMA

Sepsis can induce thrombotic microangiopathy through cytokines and granulocyte elastase that cleave ADAMTS13. Hence, some practitioners theorize that plasmapheresis might benefit sepsis-induced TMA (sTMA) by removing factors responsible for depleted ADAMTS13 levels. Indeed, systematic reviews have shown reduced short-term mortality (RR 0.59, 95% CI 0.47–0.74) when TPE was added to standard therapy in septic patients.

Yet, evidence remains insufficient for routine recommendation. The American Society for Apheresis (ASFA) provides only a category III, 2A recommendation for TPE in sepsis-induced organ dysfunction, allowing individualized use on a case-by-case basis. Specifically, sTMA typically requires fewer sessions (median of six) than primary TTP, potentially reducing catheter-related complications.

TTP plasma exchange in drug-induced TMA

Drug-induced thrombotic microangiopathies (DITMA) account for 10-13% of all TMAs and 28.5% of renal-limited TMAs. Most DITMAs resolve with drug discontinuation alone. The effectiveness of TPE varies dramatically based on the mechanism—drugs like ticlopidine that induce ADAMTS13 autoantibodies respond well (87% survival with TPE), whereas those causing direct endothelial injury like clopidogrel show poorer outcomes (50% survival with TPE).

Accordingly, ASFA classifies TPE for chemotherapy-associated TMA as category IV (ineffective) with Grade 2C evidence. For instance, gemcitabine-associated TMA showed better outcomes (65% recovery) with drug withdrawal alone compared to TPE cohorts.

Case examples of unnecessary TPE

In the Oklahoma TTP-HUS Registry, 7% of patients initially diagnosed with TTP ultimately had systemic infections causing their symptoms. All these patients received plasmapheresis despite having alternative explanations for their clinical presentation. Similarly, vitamin B12 deficiency can mimic TTP, with 38.8% of reported pseudo-TMA cases receiving unnecessary plasma therapy.

Risks and complications of inappropriate TPE

Complications occur in approximately 12.7% of plasma exchange procedures, with the most common being:

• Pruritus and urticaria (7%)
• Hypertension (1.92%)
• Hypotension (1.17%)
• Depletion coagulopathy (47.6%)
• Electrolyte imbalances—hypocalcemia (44.1%), hypokalemia (36.6%)

Serious complications, though rarer, include anaphylactic shock, toxic epidermal necrolysis, and disseminated cryptococcosis neoformans infection. A Canadian Apheresis Study documented side effects in 12% of procedures, affecting 40% of treated patients. Furthermore, mortality directly related to TPE complications has been reported at 4.4%, primarily from pulmonary hemorrhage and catheter-associated bloodstream infections.

 

Diagnostic Tools to Avoid Misuse of TPE

Precise diagnostic tools enable clinicians to distinguish true TTP from its mimics, thereby preventing unnecessary plasma exchange procedures. Early identification of conditions that do not require plasmapheresis improves patient outcomes while conserving resources.

PLASMIC score for early risk stratification

The PLASMIC score is a validated clinical prediction tool designed to rapidly identify patients at high risk for severe ADAMTS13 deficiency, a key feature of thrombotic thrombocytopenic purpura (TTP). This seven-point scoring system incorporates readily available clinical and laboratory parameters to support early diagnosis and guide urgent treatment decisions.

Each of the following components contributes one point:

1. Platelet count <30 × 10⁹/L
2. Evidence of hemolysis (elevated reticulocyte count, undetectable haptoglobin, or indirect bilirubin >2.0 mg/dL)
3. No active cancer
4. No history of solid organ or stem cell transplant
5. Mean corpuscular volume (MCV) <90 fL
6. International normalized ratio (INR) <1.5
7. Serum creatinine <2.0 mg/dL

Patients are stratified into three risk categories based on total score:

• Low risk (0–4 points): 0–4% likelihood of severe ADAMTS13 deficiency
• Intermediate risk (5 points): 5–24% likelihood
• High risk (6–7 points): 62–82% likelihood

Notably, no patients in the low-risk group were found to have severe ADAMTS13 deficiency. The tool demonstrates excellent diagnostic performance, with a c-statistic ranging from 0.91 to 0.96, indicating high accuracy.

In clinical practice, the PLASMIC score enables rapid triage of suspected TTP cases, ensuring timely initiation of plasma exchange and other life-saving therapies in high-risk patients while reducing unnecessary interventions in low-risk cases.

Role of peripheral smear and LDH

Peripheral blood smear examination remains essential for identifying schistocytes—fragmented RBCs characteristic of microangiopathic hemolytic anemia. In conjunction with thrombocytopenia, this finding constitutes a cornerstone for TTP diagnosis. Lactate dehydrogenase levels typically reach approximately 1000 IU/L in TTP, whereas values exceeding 3000 U/L often suggest vitamin B12 deficiency-associated pseudo-TMA.

Use of rapid ADAMTS13 assays

Rapid ADAMTS13 testing has emerged as a game-changer for TTP diagnosis. The HemosIL AcuStar chemiluminescent assay provides results within one hour versus 3-5 hours for ELISA methods, with sensitivity of 98% and specificity of 99%. This rapid turnaround time allows clinicians to avert unnecessary plasma exchange in patients without TTP. Even so, cost-effectiveness analyzes demonstrate savings up to $46,820 per patient tested using rapid assays, primarily by reducing inappropriate plasmapheresis and caplacizumab use.

Differentiating TTP from DIC and HUS

Unlike TTP, disseminated intravascular coagulation (DIC) typically presents with prolonged coagulation times, elevated D-dimer levels, and consumptive coagulopathy. Conversely, TTP shows normal coagulation studies. Hemolytic uremic syndrome (HUS) clinically overlaps with TTP yet primarily causes renal failure, whereas neurological manifestations predominate in TTP. However, ADAMTS13 activity remains normal in HUS patients, providing a critical differentiating factor.

 

 

Guidelines for Initiating and Stopping TPE in Suspected TTP

Effective protocols for therapeutic plasma exchange (TPE) in suspected thrombotic thrombocytopenic purpura focus on both appropriate initiation and timely discontinuation. Prompt intervention remains crucial, yet determining when to terminate treatment proves equally important in managing resources and preventing complications.

When to stop plasmapheresis in TTP mimics

TPE should be discontinued in suspected TTP cases once evidence points toward an alternative diagnosis. If LDH remains below 420 IU/L after initial assessment, there exists little rationale for continuing plasma exchange. For patients with vitamin B12 deficiency-associated pseudo-TMA, immediate cessation of TPE upon identification allows transition to appropriate B12 supplementation. Furthermore, in patients whose thrombocytopenia fails to improve after 3-5 daily TPE sessions with ADAMTS13 activity above 5-10%, treatment should be discontinued while other management options are pursued.

TTP plasmapheresis protocol: escalation and de-escalation

Standard TPE protocol involves daily exchanges of 1.0-1.5 plasma volumes until clinical response occurs. Thereafter, ongoing exchanges typically continue for at least two consecutive days after platelet normalization (≥150 × 10^9/L). Unlike previous practice, tapering of TPE frequency has not demonstrated reduction in relapse rates. For refractory cases showing inadequate response after five sessions, consideration of rituximab alongside continued TPE becomes warranted.

ASFA category III and IV indications

The American Society for Apheresis classification guides TPE use beyond true TTP. Category III indications—where TPE role remains uncertain—include complement-mediated TMA and TMA with severe neurologic symptoms. Conversely, category IV designations (ineffective or harmful) encompass Shiga toxin-mediated TMA without neurologic symptoms and chemotherapy-associated TMA. These classifications help clinicians individualize decision-making in challenging cases.

Monitoring response: platelet count and LDH trends

Response assessment relies primarily on daily monitoring of platelet count and LDH levels. Clinical improvement typically follows a predictable pattern—neurological symptoms improve first (approximately 3 days), followed by LDH normalization (around 5 days), and finally platelet recovery (median 7 days). Also, LDH may return to normal relatively faster than platelet count, making it a valuable early indicator of treatment response. Refractory TTP occurs when patients fail to achieve clinical response after five TPE sessions, defined as sustained platelet count ≥150 × 10^9/L, LDH <1.5 times upper limit of normal, and absence of new organ damage.

 

---

Conclusion

Accurately distinguishing true thrombotic thrombocytopenic purpura (TTP) from its mimics remains one of the most challenging aspects of managing thrombotic microangiopathies (TMAs). Although plasmapheresis (TPE) has significantly improved outcomes for confirmed TTP, misdiagnosis still leads to unnecessary interventions, avoidable complications, and delayed treatment of the actual underlying disorder.

Data from the Oklahoma TTP-HUS Registry underscores this diagnostic challenge—7% of patients initially diagnosed with TTP were ultimately found to have systemic infections. This highlights the need for better upfront diagnostic strategies.

Severe ADAMTS13 deficiency remains the gold standard for confirming TTP, but in most clinical settings, test results are delayed by several days. This forces clinicians to begin TPE based on clinical suspicion alone, often without diagnostic certainty. While early treatment is critical in true TTP, it can be harmful when initiated for the wrong diagnosis.

Recently developed rapid ADAMTS13 assays offer a promising solution by enabling faster, more accurate decision-making. These tests not only improve patient outcomes by targeting treatment appropriately but can also save healthcare systems up to $46,820 per patient by avoiding unnecessary TPE.

The PLASMIC score has become a reliable tool for early risk stratification when ADAMTS13 activity is pending. A score of 0–4 effectively rules out severe ADAMTS13 deficiency, signaling that alternative diagnoses—such as disseminated intravascular coagulation (DIC), hemolytic uremic syndrome (HUS), or pseudo-TMA—should be prioritized.

Supporting laboratory findings can also aid diagnosis. Peripheral smear reviews, LDH levels, platelet counts, creatinine, and coagulation profiles can all help differentiate TTP from other TMAs.

While prompt initiation of TPE is essential in suspected TTP, discontinuation is equally critical when evidence points elsewhere. If platelet counts fail to recover after 3–5 days of TPE and ADAMTS13 activity is normal, the likelihood of TTP is low. In such cases, continued plasmapheresis only adds risk and delays appropriate therapy for the actual condition.

The future of TTP management lies in faster diagnostic testing and more refined clinical prediction tools. By combining early risk assessment with emerging rapid assays, clinicians can more accurately identify true TTP, avoid overtreatment, and improve patient outcomes across the spectrum of thrombotic microangiopathies. A thoughtful, data-informed approach will ensure both urgency and precision in this high-stakes clinical scenario.

 

Frequently Asked Questions:

FAQs

Q1. When should plasmapheresis be stopped in TTP treatment? Plasmapheresis should be discontinued when the platelet count remains above 150 × 10^9/L and LDH levels are near normal for 2-3 consecutive days. In cases where an alternative diagnosis becomes evident or there’s no improvement after 3-5 daily sessions, stopping treatment should be considered.

Q2. What is the primary function of plasmapheresis in TTP management? Plasmapheresis serves as a life-saving procedure for TTP by removing harmful antibodies that damage the ADAMTS13 enzyme from the blood. It also replaces the patient’s plasma with fresh frozen plasma containing functional ADAMTS13, effectively treating the underlying cause of the condition.

Q3. How quickly does plasmapheresis typically show results in TTP patients? The response to plasmapheresis usually follows a predictable pattern. Neurological symptoms often improve first (around 3 days), followed by LDH normalization (about 5 days), and finally platelet recovery (median 7 days). However, individual responses may vary.

Q4. What conditions can be mistaken for TTP? Several conditions can mimic TTP, leading to potential misdiagnosis. These include systemic infections, disseminated malignancies, malignant hypertension, systemic lupus erythematosus, and certain renal disorders. Careful diagnostic evaluation is necessary to differentiate TTP from these mimics.

Q5. How effective are rapid ADAMTS13 assays in diagnosing TTP? Rapid ADAMTS13 assays have shown high effectiveness in diagnosing TTP, with sensitivity of 98% and specificity of 99%. These tests can provide results within an hour, allowing for quicker decision-making and potentially reducing unnecessary plasmapheresis in non-TTP cases.

 

 

---

References: